Bharat Serums secures nod to test sepsis drug on Covid-19 patients

Injectable drug is already available in the market; firm has no plans to work on vaccine candidate

Joining the list of drugs repurposed for Covid-19, a sepsis drug from Bharat Serums and Vaccines (BSVL) is getting into Phase III clinical trials.

The Mumbai-based biopharmaceutical firm — backed by US private equity player Advent International — has got approval from the drug regulator to start trials on the injectable drug that it sells under the brand U-Tryp. BSVL is not working on any Covid-19 vaccine and has no plans to do so.

Speaking to Business Standard, BSVL Managing Director and Chief